PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Completes Regular Quarterly Dividend Payment
PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note
PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit
PDL BioPharma to Hold Annual Meeting of Stockholders on May 28, 2015
PDL BioPharma Announces Fourth Quarter and Full Year 2014 Financial Results